We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.

Age-associated muscle decline can start as early as 40 years old and there are currently no effective interventions to counteract it other than exercise. A new milestone study published today in Cell Reports Medicine showed that daily intake of Amazentis' proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months. These findings further validate Mitopure's benefits for muscle and mitochondrial health and show it is safe and well tolerated. Mitopure works by supporting the cells' ability to renew their powerplants, the mitochondria, during the aging process. Muscles have a high demand for energy and there are a very large number of mitochondria in muscle cells.

Previous research showed that Mitopure improved muscle endurance, reduced inflammation, and resulted in healthier mitochondrial function in older adults 65 to 90 years old. This new double-blind, placebo-controlled trial in middle-aged adults 40 to 64 years old (n=88) was conducted in London, Ontario, Canada following approvals from Health Canada and an independent IRB. Participants were randomized to receive daily supplementation with either 500mg, 1,000mg Mitopure or placebo for 4 months. Muscle strength, exercise performance tests and biomarkers of healthy mitochondrial function and inflammation in skeletal muscle biopsies and blood plasma were assessed at baseline, 2 months and 4 months.

These results are exciting because this is the first in human demonstration that Urolithin A repairs the mitochondria via mitophagy and can translate to meaningful physiological benefits. Furthermore, the improvement in strength and exercise-performance occurred in the absence of any changes to participants exercise routine."

Johan Auwerx, MD, PhD, EPFL professor, co-author

This is an important discovery in longevity and muscle health research. Aging is associated with a decline in mitochondrial function which can lead to reduced exercise capacity, muscle endurance and strength. Urolithin A is the first and only compound that has been clinically shown to improve muscle function by renewing the mitochondria through a potent biological quality control mechanism called mitophagy. By activating this important biological pathway, Mitopure promotes healthy aging and improved muscle health and performance.

"This study further validates the role of mitochondrial health as an important pillar of vitality and shows Mitopure is a first in class nutrient that meaningfully impacts muscle health. We are proud to offer this proprietary form of Urolithin A in our Timeline® brand and inside Nestlé Health Science products," said Chris Rinsch, CEO and Co-Founder of Amazentis. "We remain committed to pioneering clinically validated products that optimize cellular health with the mission of keeping millions of people healthier for longer".

"Mitochondrial decline is a key hallmark of aging and poor metabolic health. This study is an important milestone and shows that Urolithin A could be a gamechanger in our field." said. Dr. Eric Verdin, the president and chief executive officer of the Buck Institute for Research on Aging, who just joined the Amazentis scientific advisory board.

Ecole Polytechnique Fédérale de Lausanne

Singh, A., et al. (2022) Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. doi.org/10.1016/j.xcrm.2022.100633.

Posted in: Drug Trial News | Medical Science News

Tags: Aging, Blood, Cell, Clinical Trial, Compound, Exercise, Inflammation, Knee, Medicine, Mitochondria, Muscle, Oxygen, Placebo, Research

In this interview, we speak to Martin Mangold, an applications specialist at BMG LABTECH, about their microplate readers and the essential role they play within life sciences research.

In this interview, News-Medical speaks to Thanh T. Nguyen, a project manager at Innocore Pharmaceuticals, about the mechanisms behind long-acting injectables.

In this interview, we speak to Dr. Damini Dey from Cedars-Sinai Medical Center about their latest research that involved using AI to predict heart attacks.

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

This site complies with the HONcode standard for trustworthy health information: verify here.

News-Medical.net - An AZoNetwork Site

Owned and operated by AZoNetwork, © 2000-2022